NantKwest Announces Proposed Public Offering of Common Stock
25 6월 2020 - 5:15AM
Business Wire
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer
cell-based therapeutics company, today announced that it intends to
offer and sell, subject to market and other conditions, shares of
its common stock in an underwritten public offering. In addition,
NantKwest expects to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of common stock
offered in the offering. NantKwest intends to use the net proceeds
of the offering for clinical development, manufacturing, upgrades
to its facilities and equipment, and other working capital, capital
expenditures and for general corporate purposes. All of the shares
are being offered by NantKwest. There can be no assurance as to
whether or when the offering may be completed, or the actual size
or terms of the offering.
Piper Sandler & Co. is acting as the sole bookrunning
manager for the offering. LifeSci Capital is acting as co-manager
for the offering.
A shelf registration statement on Form S-3 relating to the
common stock offered in the public offering described above was
filed with the Securities and Exchange Commission (SEC) on August
23, 2019 and declared effective by the SEC on September 3, 2019.
The proposed offering is being made only by means of a prospectus
supplement and accompanying prospectus that form a part of the
registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus relating to the offering, when available, may also be
obtained from Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via
telephone at (800) 747-3924 or via email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements regarding
NantKwest’s expectations with respect to the completion, timing and
size of the proposed public offering, the grant to the underwriters
of an option to purchase additional shares and the anticipated use
of the net proceeds from the proposed offering. Risks and
uncertainties related to these endeavors include, but are not
limited to, risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed public offering.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are
described in detail in its SEC filings, including in NantKwest’s
Current Report on Form 8-K to be filed on June 24, 2020. These
forward-looking statements speak only as of the date hereof, and we
disclaim any obligation to update these statements except as may be
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200624005815/en/
Sarah Singleton 1 (844) 696-5235, option 5
Sarah.Singleton@nantkwest.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024